Contiflo Icon is prescribed for the management of the signs and symptoms associated with benign prostatic hyperplasia (BPH) in men. BPH is the non-cancerous enlargement of the prostate gland.

Quick Facts

• Primary Use: Management of BPH symptoms.
• Aids in: Easing difficulty with urination.
• Supports: The reduction of urinary frequency and urgency, including at night.

This medication may help relieve the lower urinary tract symptoms that can be related to an enlarged prostate, such as a weak urine stream or the sensation of incomplete bladder emptying. By assisting with these symptoms, the medication supports an improved quality of life for individuals with BPH. The drug works by affecting certain pathways in the body to help the urinary flow, but it does not reduce the overall size of the prostate gland.

Official Eligibility and Restrictions

Contiflo Icon (tamsulosin hydrochloride) is an alpha-blocker intended for use only in adult male patients. Regulatory labeling explicitly defines the following populations that must not use the medicine or require special caution:

---

Classification	Population/Condition
Contraindicated (Must not use)	Known hypersensitivity (allergy) to tamsulosin or any ingredient.
	History of orthostatic hypotension (low blood pressure on standing, leading to fainting/dizziness).
	Severe hepatic insufficiency (severe liver problems).
	Women, children, and adolescents (under 18 years of age).
Caution Required (Special consideration)	Severe renal impairment (severe kidney problems; use has not been studied).
	Patients scheduled for cataract or glaucoma surgery (risk of Intraoperative Floppy Iris Syndrome, IFIS).
	Concomitant use with certain strong CYP3A4 inhibitors (e.g., ketoconazole) is not recommended.

---

Use in females is strictly prohibited, including during pregnancy and lactation, as the medicine is not indicated for this population. Patients with a history of sulfa allergies should use caution, as allergic reactions have been rarely reported in this group. It is essential for all patients to inform their healthcare provider about any prior medical conditions, especially severe liver or kidney dysfunction, and any upcoming eye surgeries.

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Contiflo Icon (Tamsulosin) based on regulatory information. All restrictions are stated according to official prescribing information.

---

Formally Contraindicated Combinations

Co-administration with certain medications is strictly prohibited due to significant interaction risks:

• Strong Inhibitors of CYP3A4 (e.g., Ketoconazole): Use with Tamsulosin is formally prohibited due to the risk of substantially increased exposure to Tamsulosin.
• Other Alpha-Adrenergic Blocking Agents (e.g., Doxazosin, Alfuzosin): Prohibited due to the potential for excessive lowering of blood pressure (symptomatic hypotension).

---

Documented Pharmacokinetic and Pharmacodynamic Interactions

Interactions are primarily related to the drug's metabolism via the CYP3A4 and CYP2D6 enzyme pathways or additive blood pressure effects.

Interacting Product Category	Example Medicines	Official Requirement
CYP2D6 Inhibitors (Strong/Moderate)	Paroxetine, Terbinafine	Use with caution due to increased Tamsulosin levels.
Phosphodiesterase-5 (PDE5) Inhibitors	Sildenafil, Tadalafil	Use with caution due to potential for additive hypotensive effects.
Cimetidine	N/A	Caution is advised as it can increase Tamsulosin exposure.

---

Population and Administration Notes

Caution is specifically noted for individuals identified as CYP2D6 Poor Metabolizers due to the higher systemic exposure risk. Tamsulosin capsules must be administered after the first meal of the day.

Selective alpha1-Adrenergic Receptor Blockade

Contiflo Icon's mechanism centers on acting as a selective antagonist for the Alpha-1A (alpha1A) adrenergic receptors found predominantly on the smooth muscle of the prostate and bladder neck. This molecular blockade interrupts the signaling that normally causes muscle contraction, by preventing the endogenous neurotransmitter Norepinephrine from binding to and activating the receptor.

---

Inhibition of Muscle Contraction Cascade

The suppression of the alpha1A-receptor signaling cascade prevents the mobilization of intracellular Calcium ions ( Ca^2+), which are essential for the smooth muscle cells to contract. By inhibiting this key step, the drug forces the peri-urethral smooth muscle tissue into a state of relaxation. This physiological change drives the systemic consequence of reduced tissue stiffness and a decrease in resistance to outflow.

---

Modulation of Dynamic Urethral Resistance

The resulting relaxation of the smooth muscle tissue produces a direct and measurable decrease in the dynamic resistance to the outflow of urine through the urethra. This mechanism focuses entirely on altering the muscle tone component of the obstruction, leading to a physical widening of the urinary channel without affecting the underlying structural volume of the prostate tissue itself.

How to Use Contiflo Icon

Contiflo Icon (Tamsulosin) is administered according to standardized instructions which dictate the dose, frequency, and administration method.

---

Administration Scope

Usage Parameter	Standard Guideline
Route of Administration	Oral administration.
Dosing Schedule	Therapy starts at 0.4 mg once daily. The dose may be increased to a maximum maintenance dose of 0.8 mg once daily if the response is insufficient after 2 to 4 weeks.
Timing with Food	The capsule must be administered approximately one-half hour following the same meal each day.
Preparation	The prolonged-release capsule must be swallowed whole and must not be crushed, chewed, or opened.
Pediatric Use	The medicine is not indicated for use in pediatric patients (under 18 years of age).
Interrupted Therapy	If administration is interrupted for several days, re-starting therapy should begin again at the initial 0.4 mg once-daily dose.
Population Adjustment	No dose adjustment is generally warranted in patients with mild to moderate renal or hepatic impairment.

---

Usage Protocol

This medication is structured for once-daily administration, making it suitable for long-term use in managing symptoms. The precise timing of administration one-half hour after the same meal each day is a key requirement to ensure consistent release and absorption of the prolonged-release formulation. The standardized initial dose of 0.4 mg and the structured, time-dependent titration process to a maximum of 0.8 mg are intended to guide the use of the medicine.

Research Evidence / Overview of Studies for Contiflo Icon (Tamsulosin)

Research Evidence for Lower Urinary Tract Symptoms (LUTS) in BPH

Research on the active component of Contiflo Icon, Tamsulosin, primarily consists of numerous Randomized Controlled Trials (RCTs). These studies were designed to evaluate the medicine's role related to the signs and symptoms associated with Benign Prostatic Hyperplasia (BPH) in adult men. Researchers monitored and measured changes in patient-reported experiences using standardized questionnaires, such as the International Prostate Symptom Score (IPSS), to track symptom measurements over time. They also used objective functional measures, such as tracking the maximum urinary flow rate (Q max) and the volume of urine remaining after voiding (PVR), to evaluate physical measurements.

The findings from these controlled studies describe patterns observed in the research groups. This evidence describes symptom measurements for conditions characterized by functional limitations. While a high volume of consistent evidence is available, existing studies provide limited insight into whether the medication alters the long-term clinical progression of BPH, such as conclusively reducing the need for prostate-related surgery.

---

Research Evidence for Acute Urinary Retention (AUR)

Research has also explored the active component in the acute clinical situation of Acute Urinary Retention (AUR). Studies include randomized, prospective trials that examined the medicine's use as an adjunct therapy in men who had a catheter removed (a Trial of Voiding Without Catheter, or TWOC).

The primary outcome monitored in these studies was the rate of voiding during a TWOC. Scientific literature described the patterns of voiding observed in studies that compared the medicine's use to a control group during the immediate post-catheterization phase. However, the evidence is limited for this specific, acute use. Follow-up durations were very short-term, typically only covering the immediate period after the catheter was removed.

---

Long-Term Follow-up and Durability of Observed Changes

In addition to short-term trials, research has been conducted to monitor patients over longer periods, typically one year or more, through extended-duration studies. Studies monitored how patient-reported outcomes evolved over defined time intervals to better understand the durability of observed changes. However, long-term effects are not fully established. There is limited information specifically from long-term, direct comparative trials, and the existing evidence primarily helps contextualize how symptom measurements are taken over extended durations.

Key Studies & References

1. Tamsulosin hydrochloride capsule: FDA Label and Full Prescribing Information

Common questions about Contiflo Icon (FAQ)

---

Q: What is the active ingredient in Contiflo Icon and what is it used for?

The active substance in Contiflo Icon is tamsulosin hydrochloride. It is a type of medicine known as an alpha-blocker. According to the official product information, it is used to treat symptoms associated with Benign Prostatic Hyperplasia (BPH), which is the enlargement of the prostate gland. These symptoms typically include difficulty passing urine.

---

Q: Is Contiflo Icon available over the counter, or does it require a prescription?

Contiflo Icon (tamsulosin) is designated as a prescription-only medicine. This means that a valid prescription from a qualified healthcare provider is required before it can be dispensed by a pharmacy. This classification is standard for medicines used to manage conditions like Benign Prostatic Hyperplasia (BPH).

---

Q: Does Contiflo Icon cause dizziness or lightheadedness when changing positions?

Official information indicates that Contiflo Icon may cause an effect called orthostatic hypotension. This is a drop in blood pressure that can lead to dizziness or lightheadedness when a person suddenly sits up or stands up from a lying position. Regulatory documents advise that patients should be made aware of this potential side effect, particularly at the start of treatment.

---

Q: What should I do if I miss a dose of Contiflo Icon?

According to the official guidance, if the missed dose is remembered later on the same day, the official product information states the tablet should be taken immediately. However, if the dose is not remembered until the next day, it states that the next dose should be taken as usual. The official documentation strictly advises against taking a double dose to compensate for the forgotten one.

---

Q: Can Contiflo Icon affect a patient's eyes or vision?

Regulatory documents mention that tamsulosin, the active ingredient, has been associated with a complication during eye surgery known as Intraoperative Floppy Iris Syndrome (IFIS), specifically during cataract or glaucoma procedures. The product information states that patients planning surgery are advised to inform their eye surgeon if they are taking or have previously taken Contiflo Icon.

Storage and Disposal Requirements

Contiflo Icon (tamsulosin hydrochloride) must be stored and disposed of strictly according to official regulatory guidelines to maintain its stability and ensure safety.

---

Storage Conditions

The capsules must be kept at room temperature, specifically below 25 °C, and protected from excess heat and moisture. It is mandatory to keep the medicine from freezing. The medication must remain in the container it came in, tightly closed, and out of the sight and reach of children. Do not use the product after the expiry date shown on the packaging.

---

Disposal Instructions

Official regulations require that unused or expired capsules not be thrown away via wastewater or household waste. Disposal must be performed in accordance with local regulations by consulting a pharmacist for appropriate pharmaceutical waste collection procedures.